Allergan and Molecular Partners’ drug for neovascular age-related macular degeneration met the main goal in two late-stage studies.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.
Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.
Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.
AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.
PainReform received FDA clearance to begin late-stage studies for a pain-relief drug that is a departure from opiate-based narcotics.
Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.
CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.
Japanese drugmaker Eisai Co. and Biogen Inc. said the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.
Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.
Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.
Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.
Britain’s Summit Therapeutics will stop developing the company’s Duchenne muscular dystrophy drug after ezutromid failed a mid-stage study, wiping out nearly 80 percent of its market value.
Aquinox Pharmaceuticals Inc. plans to stop developing its main drug to treat bladder pain syndrome as rosiptor failed to meet the main goal of a late-stage trial, pushing the company’s shares down as much as 85 percent.
AstraZeneca’s oncology business received a boost as results of a clinical trial showed the company’s drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.
Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.
A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.
Eli Lilly and Co.’s Jardiance, along with insulin therapy, met the main goal of two trials testing the company’s drug in patients with type 1 diabetes.
Merrimack Pharmaceuticals Inc. will stop developing the company’s experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.